Benjamin Frank
Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 20 | 2026 | 1980 | 3.770 |
Why?
| | Echocardiography | 9 | 2026 | 652 | 1.830 |
Why?
| | Heart Defects, Congenital | 14 | 2025 | 914 | 1.760 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2022 | 392 | 1.600 |
Why?
| | Pulmonary Artery | 11 | 2025 | 1134 | 1.310 |
Why?
| | Hernias, Diaphragmatic, Congenital | 2 | 2023 | 219 | 1.240 |
Why?
| | Ventricular Dysfunction, Right | 5 | 2026 | 248 | 1.200 |
Why?
| | Fontan Procedure | 5 | 2024 | 191 | 1.160 |
Why?
| | Endothelin-1 | 2 | 2022 | 184 | 1.160 |
Why?
| | Heart Ventricles | 11 | 2026 | 760 | 1.110 |
Why?
| | Kynurenine | 3 | 2024 | 114 | 1.010 |
Why?
| | Cardiopulmonary Bypass | 8 | 2025 | 221 | 0.990 |
Why?
| | Tryptophan | 3 | 2024 | 181 | 0.970 |
Why?
| | Heart Septal Defects | 1 | 2026 | 13 | 0.960 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 560 | 0.920 |
Why?
| | Infant | 23 | 2025 | 10034 | 0.860 |
Why?
| | Hemodynamics | 11 | 2025 | 1121 | 0.860 |
Why?
| | Cardiac Surgical Procedures | 6 | 2024 | 609 | 0.850 |
Why?
| | Acetamides | 1 | 2024 | 37 | 0.840 |
Why?
| | Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.810 |
Why?
| | Citrulline | 1 | 2024 | 46 | 0.810 |
Why?
| | Nitric Oxide | 3 | 2024 | 897 | 0.810 |
Why?
| | Pyrazines | 1 | 2024 | 92 | 0.800 |
Why?
| | Arginine | 1 | 2024 | 262 | 0.740 |
Why?
| | Blood Proteins | 2 | 2020 | 249 | 0.740 |
Why?
| | Aortic Coarctation | 2 | 2023 | 79 | 0.730 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2024 | 383 | 0.720 |
Why?
| | Heart Bypass, Right | 1 | 2022 | 17 | 0.720 |
Why?
| | Infant, Premature, Diseases | 2 | 2023 | 111 | 0.710 |
Why?
| | Child | 31 | 2026 | 22633 | 0.710 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2025 | 410 | 0.690 |
Why?
| | Ventricular Function, Left | 4 | 2023 | 541 | 0.650 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2020 | 67 | 0.640 |
Why?
| | Heart Diseases | 1 | 2023 | 349 | 0.630 |
Why?
| | Heart Function Tests | 1 | 2019 | 59 | 0.610 |
Why?
| | Infant, Newborn | 15 | 2025 | 6429 | 0.590 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 22 | 0.580 |
Why?
| | Scurvy | 1 | 2019 | 17 | 0.580 |
Why?
| | Prospective Studies | 11 | 2024 | 7990 | 0.570 |
Why?
| | Atrial Function, Right | 3 | 2025 | 14 | 0.560 |
Why?
| | Biomarkers | 8 | 2024 | 4271 | 0.550 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2019 | 124 | 0.550 |
Why?
| | Humans | 61 | 2026 | 144759 | 0.550 |
Why?
| | Ventricular Function, Right | 4 | 2026 | 297 | 0.540 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 338 | 0.530 |
Why?
| | Pediatrics | 2 | 2024 | 1114 | 0.500 |
Why?
| | Ventricular Remodeling | 1 | 2019 | 276 | 0.490 |
Why?
| | Magnetic Resonance Imaging, Cine | 4 | 2025 | 214 | 0.440 |
Why?
| | Retrospective Studies | 16 | 2025 | 17066 | 0.420 |
Why?
| | Treatment Outcome | 11 | 2025 | 11679 | 0.420 |
Why?
| | Pain | 1 | 2019 | 779 | 0.390 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2022 | 197 | 0.390 |
Why?
| | Computed Tomography Angiography | 2 | 2025 | 145 | 0.380 |
Why?
| | Male | 30 | 2026 | 72315 | 0.380 |
Why?
| | Adolescent | 17 | 2025 | 22428 | 0.370 |
Why?
| | Predictive Value of Tests | 8 | 2026 | 2115 | 0.370 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.360 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2025 | 120 | 0.350 |
Why?
| | Child, Preschool | 12 | 2026 | 11787 | 0.350 |
Why?
| | Female | 30 | 2026 | 78271 | 0.350 |
Why?
| | Pulmonary Veins | 2 | 2023 | 105 | 0.330 |
Why?
| | Vasodilator Agents | 2 | 2025 | 331 | 0.320 |
Why?
| | Hypoxia | 3 | 2024 | 1199 | 0.320 |
Why?
| | Heart Failure | 1 | 2024 | 2323 | 0.320 |
Why?
| | Myocardial Contraction | 3 | 2020 | 298 | 0.320 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 510 | 0.320 |
Why?
| | Case-Control Studies | 5 | 2025 | 3604 | 0.300 |
Why?
| | Microfilament Proteins | 4 | 2003 | 135 | 0.300 |
Why?
| | Pulmonary Valve | 1 | 2010 | 101 | 0.290 |
Why?
| | Length of Stay | 4 | 2025 | 1337 | 0.290 |
Why?
| | Postoperative Complications | 5 | 2021 | 2919 | 0.270 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 2 | 2025 | 26 | 0.260 |
Why?
| | Prognosis | 4 | 2026 | 4282 | 0.250 |
Why?
| | Arterial Pressure | 2 | 2025 | 136 | 0.250 |
Why?
| | Tissue Engineering | 1 | 2010 | 442 | 0.240 |
Why?
| | Magnetic Resonance Imaging | 8 | 2026 | 3863 | 0.240 |
Why?
| | Morbidity | 2 | 2024 | 323 | 0.240 |
Why?
| | Palliative Care | 3 | 2025 | 1002 | 0.230 |
Why?
| | Carrier Proteins | 4 | 2003 | 737 | 0.230 |
Why?
| | Stroke Volume | 3 | 2025 | 651 | 0.230 |
Why?
| | Vascular Stiffness | 2 | 2021 | 486 | 0.230 |
Why?
| | Proteomics | 2 | 2023 | 1195 | 0.220 |
Why?
| | Multimodal Imaging | 1 | 2026 | 124 | 0.220 |
Why?
| | Chorioamnionitis | 1 | 2025 | 45 | 0.220 |
Why?
| | Serotonin | 2 | 2024 | 293 | 0.220 |
Why?
| | SOXF Transcription Factors | 1 | 2024 | 16 | 0.220 |
Why?
| | Kynurenic Acid | 1 | 2024 | 18 | 0.220 |
Why?
| | Norwood Procedures | 1 | 2025 | 29 | 0.220 |
Why?
| | Multidetector Computed Tomography | 1 | 2025 | 40 | 0.220 |
Why?
| | Hemorrhage | 2 | 2021 | 809 | 0.220 |
Why?
| | Graft Occlusion, Vascular | 1 | 2025 | 42 | 0.220 |
Why?
| | Echocardiography, Doppler | 1 | 2025 | 115 | 0.210 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 28 | 0.200 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 865 | 0.200 |
Why?
| | History, 21st Century | 1 | 2024 | 219 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 41 | 0.190 |
Why?
| | Models, Cardiovascular | 2 | 2024 | 195 | 0.190 |
Why?
| | Vascular Resistance | 1 | 2024 | 367 | 0.190 |
Why?
| | Stenosis, Pulmonary Vein | 1 | 2023 | 19 | 0.190 |
Why?
| | History, 20th Century | 1 | 2024 | 325 | 0.190 |
Why?
| | Infant, Extremely Premature | 1 | 2023 | 67 | 0.190 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2022 | 40 | 0.180 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 158 | 0.180 |
Why?
| | Atrioventricular Block | 1 | 2022 | 45 | 0.180 |
Why?
| | Phenylpropionates | 1 | 2022 | 27 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.180 |
Why?
| | Pyridazines | 1 | 2022 | 57 | 0.170 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 19 | 0.170 |
Why?
| | Fetal Diseases | 1 | 2023 | 191 | 0.170 |
Why?
| | Protein Conformation | 2 | 2003 | 946 | 0.170 |
Why?
| | Phosphoproteins | 1 | 2003 | 344 | 0.170 |
Why?
| | Risk Factors | 5 | 2025 | 10779 | 0.170 |
Why?
| | Amino Acids | 1 | 2025 | 521 | 0.170 |
Why?
| | Administration, Inhalation | 2 | 2021 | 574 | 0.170 |
Why?
| | Ventricular Function | 1 | 2021 | 57 | 0.170 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 286 | 0.170 |
Why?
| | Lung | 4 | 2025 | 4109 | 0.170 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2003 | 630 | 0.170 |
Why?
| | Postoperative Period | 1 | 2022 | 354 | 0.170 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 98 | 0.160 |
Why?
| | Pulmonary Atresia | 1 | 2020 | 22 | 0.160 |
Why?
| | Preoperative Period | 1 | 2020 | 149 | 0.160 |
Why?
| | Heart Atria | 1 | 2021 | 144 | 0.150 |
Why?
| | Proteome | 1 | 2024 | 518 | 0.150 |
Why?
| | Electrophysiological Phenomena | 1 | 2019 | 60 | 0.150 |
Why?
| | Metabolomics | 3 | 2021 | 727 | 0.150 |
Why?
| | Societies, Medical | 1 | 2024 | 887 | 0.150 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 253 | 0.150 |
Why?
| | Mechanical Phenomena | 1 | 2019 | 80 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2023 | 553 | 0.150 |
Why?
| | Gingiva | 1 | 2019 | 25 | 0.150 |
Why?
| | Regional Blood Flow | 1 | 2021 | 514 | 0.140 |
Why?
| | Coronary Care Units | 1 | 2018 | 26 | 0.140 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 383 | 0.140 |
Why?
| | Cholecalciferol | 1 | 2019 | 60 | 0.140 |
Why?
| | Infant, Premature | 2 | 2023 | 611 | 0.140 |
Why?
| | Alkaline Phosphatase | 1 | 2019 | 145 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 279 | 0.140 |
Why?
| | Chest Pain | 1 | 2019 | 99 | 0.140 |
Why?
| | Endotoxemia | 1 | 2019 | 87 | 0.140 |
Why?
| | Transcriptome | 1 | 2025 | 1045 | 0.140 |
Why?
| | Endotoxins | 1 | 2019 | 221 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 710 | 0.130 |
Why?
| | Ascorbic Acid | 1 | 2019 | 180 | 0.130 |
Why?
| | Leg | 1 | 2019 | 239 | 0.130 |
Why?
| | Heart Transplantation | 1 | 2023 | 736 | 0.120 |
Why?
| | Cohort Studies | 2 | 2024 | 5960 | 0.120 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 594 | 0.120 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 780 | 0.120 |
Why?
| | Risk | 1 | 2019 | 911 | 0.120 |
Why?
| | Iron | 1 | 2019 | 359 | 0.120 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 1997 | 106 | 0.120 |
Why?
| | Swine | 3 | 2025 | 833 | 0.120 |
Why?
| | Actins | 3 | 2003 | 425 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 576 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1325 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2019 | 576 | 0.110 |
Why?
| | Lung Diseases | 1 | 2021 | 787 | 0.110 |
Why?
| | Intubation, Intratracheal | 1 | 1997 | 320 | 0.100 |
Why?
| | Down Syndrome | 1 | 2021 | 534 | 0.100 |
Why?
| | Stents | 2 | 2025 | 556 | 0.100 |
Why?
| | Time Factors | 3 | 2021 | 7173 | 0.100 |
Why?
| | Inflammation | 1 | 2025 | 2878 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 920 | 0.100 |
Why?
| | Blood Pressure | 1 | 2019 | 1769 | 0.090 |
Why?
| | Amino Acid Sequence | 4 | 2003 | 2155 | 0.090 |
Why?
| | Molecular Sequence Data | 4 | 2003 | 2930 | 0.080 |
Why?
| | Diastole | 2 | 2022 | 143 | 0.080 |
Why?
| | Purines | 2 | 2022 | 187 | 0.080 |
Why?
| | Drainage | 1 | 2011 | 185 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2019 | 956 | 0.080 |
Why?
| | Cell Count | 1 | 2010 | 320 | 0.080 |
Why?
| | Bile Duct Neoplasms | 1 | 2011 | 127 | 0.080 |
Why?
| | Adult | 4 | 2023 | 40449 | 0.080 |
Why?
| | Anastomosis, Surgical | 2 | 2021 | 157 | 0.080 |
Why?
| | Cholestasis | 1 | 2011 | 219 | 0.070 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2002 | 346 | 0.070 |
Why?
| | Peptide Fragments | 2 | 2003 | 699 | 0.070 |
Why?
| | Metabolome | 2 | 2021 | 384 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3409 | 0.060 |
Why?
| | Keratan Sulfate | 1 | 2006 | 1 | 0.060 |
Why?
| | Histidine | 2 | 2003 | 66 | 0.060 |
Why?
| | Synovial Fluid | 1 | 2006 | 67 | 0.060 |
Why?
| | Protein Folding | 3 | 2002 | 279 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 142 | 0.060 |
Why?
| | Circular Dichroism | 2 | 2002 | 150 | 0.060 |
Why?
| | Age Factors | 2 | 2025 | 3333 | 0.050 |
Why?
| | Organ Specificity | 1 | 2025 | 312 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 208 | 0.050 |
Why?
| | Language Development | 1 | 2024 | 60 | 0.050 |
Why?
| | Syndrome | 1 | 2024 | 380 | 0.050 |
Why?
| | Vena Cava, Inferior | 1 | 2024 | 81 | 0.050 |
Why?
| | Erythrocyte Membrane | 1 | 2003 | 54 | 0.050 |
Why?
| | Osteoarthritis | 1 | 2006 | 196 | 0.050 |
Why?
| | Models, Molecular | 3 | 2003 | 1618 | 0.050 |
Why?
| | Vascular Remodeling | 1 | 2025 | 205 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2496 | 0.050 |
Why?
| | Serine | 1 | 2003 | 145 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3890 | 0.050 |
Why?
| | Binding Sites | 2 | 2003 | 1329 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2002 | 862 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2025 | 902 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 499 | 0.050 |
Why?
| | Animals | 6 | 2025 | 38058 | 0.050 |
Why?
| | Tadalafil | 1 | 2022 | 6 | 0.050 |
Why?
| | Pulmonary Circulation | 1 | 2024 | 430 | 0.050 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 85 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2022 | 35 | 0.040 |
Why?
| | Phenylalanine | 1 | 2002 | 71 | 0.040 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2021 | 17 | 0.040 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 192 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 381 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2002 | 304 | 0.040 |
Why?
| | Niacinamide | 1 | 2021 | 86 | 0.040 |
Why?
| | Methionine | 1 | 2021 | 162 | 0.040 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2020 | 34 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 45 | 0.040 |
Why?
| | Systole | 1 | 2020 | 178 | 0.040 |
Why?
| | Gestational Age | 1 | 2023 | 975 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 1025 | 0.040 |
Why?
| | Survival Rate | 2 | 2011 | 2089 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2025 | 2527 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2020 | 136 | 0.040 |
Why?
| | Aortic Valve | 1 | 2022 | 365 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 197 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1732 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 675 | 0.040 |
Why?
| | Time | 1 | 2019 | 86 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1047 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 454 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 662 | 0.030 |
Why?
| | Myocardium | 1 | 2023 | 939 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1782 | 0.030 |
Why?
| | Electrophysiologic Techniques, Cardiac | 1 | 2018 | 84 | 0.030 |
Why?
| | Nevada | 1 | 1997 | 8 | 0.030 |
Why?
| | Aorta | 1 | 2020 | 429 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1886 | 0.030 |
Why?
| | Escherichia coli | 1 | 2002 | 854 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2025 | 2925 | 0.030 |
Why?
| | Poisson Distribution | 1 | 1997 | 78 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2018 | 413 | 0.030 |
Why?
| | Thrombophlebitis | 1 | 1997 | 12 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2020 | 750 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1169 | 0.030 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 1997 | 40 | 0.030 |
Why?
| | United States | 2 | 2025 | 15966 | 0.030 |
Why?
| | Arthroplasty | 1 | 1997 | 59 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1997 | 333 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5597 | 0.030 |
Why?
| | Liver | 1 | 2025 | 1887 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1560 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1997 | 285 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2018 | 583 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4557 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1495 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 1030 | 0.030 |
Why?
| | Oxygen | 1 | 2018 | 995 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2730 | 0.020 |
Why?
| | Pregnancy | 1 | 2025 | 7190 | 0.020 |
Why?
| | Retreatment | 1 | 2011 | 77 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5408 | 0.020 |
Why?
| | Catheterization | 1 | 2011 | 183 | 0.020 |
Why?
| | Chickens | 2 | 2002 | 191 | 0.020 |
Why?
| | Incidence | 1 | 1997 | 2879 | 0.020 |
Why?
| | Radiography, Interventional | 1 | 2011 | 130 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3671 | 0.020 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2006 | 12 | 0.020 |
Why?
| | Protein Binding | 2 | 2002 | 2273 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 797 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 2011 | 8265 | 0.010 |
Why?
| | Autoantigens | 1 | 2006 | 429 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 14105 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 2002 | 131 | 0.010 |
Why?
| | Knee Joint | 1 | 2006 | 426 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 331 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 396 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 379 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2002 | 195 | 0.010 |
Why?
| | Titrimetry | 1 | 1999 | 12 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1999 | 74 | 0.010 |
Why?
| | Static Electricity | 1 | 1999 | 113 | 0.010 |
Why?
| | Solvents | 1 | 1999 | 113 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 1999 | 224 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2002 | 388 | 0.010 |
Why?
| | Temperature | 1 | 2002 | 679 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1999 | 369 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1370 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1627 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1999 | 561 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2027 | 0.010 |
Why?
| | Thermodynamics | 1 | 1999 | 426 | 0.010 |
Why?
| | Software | 1 | 2002 | 690 | 0.010 |
Why?
| | Case Management | 1 | 1997 | 67 | 0.010 |
Why?
| | Aged | 2 | 2011 | 25913 | 0.010 |
Why?
| | Middle Aged | 2 | 2011 | 35875 | 0.010 |
Why?
| | Population Surveillance | 1 | 1997 | 485 | 0.010 |
Why?
|
|
Frank's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|